Imigran Dosage/Direction for Use

Adults: IMIGRAN is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically. The recommended dose of IMIGRAN should not be exceeded.
It is advisable that IMIGRAN be given as early as possible after the onset of migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose of oral IMIGRAN is a 50 mg tablet. Some patients may require 100 mg.
If the patient has responded to the first dose but the symptoms recur a second dose may be provided that there is a minimum interval of two hours between the two doses. No more than 300 mg should be taken in any 24 hour period.
Patients who do not respond to the prescribed dose of IMIGRAN should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. IMIGRAN may be taken for subsequent attacks.
IMIGRAN is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see Contraindications).
The tablets should be swallowed whole with water.
Paediatric population: The efficacy and safety of IMIGRAN in children aged less than 10 years have not been established. No clinical data are available in this age group.
The efficacy and safety of IMIGRAN in children 10 to 17 years of age have not been demonstrated in the clinical trials performed in this age group. Therefore the use of IMIGRAN in children 10 to 17 years of age is not recommended (see Pharmacology: Pharmacodynamics under Actions).
Elderly (Over 65 Years of age): Experience of the use of IMIGRAN in patients aged over 65 years is limited. The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of IMIGRAN in patients aged over 65 years is not recommended.